MIRM Mirum Pharmaceuticals, Inc.

NEUTRAL Impact: 3/10 144
Horizon days Filed Jun 1, 2026 Processed 13d 11h ago SEC 0001950047-26-005448
Form 144 — notice of proposed sale of securities
Latest settled — T+1d ⚠ clustered
MIRM ▼ -0.36% at T+1d
NEUTRAL call ✗ call lost -0.36% · α vs SPY +0.36% · entry $92.17 → $91.84
Next anchor: T+5d due 7d ago
Last close $99.35 (close Jun 12) · +7.78% from $92.17 entry
Entry anchored
Jun 1, 2026
via day open
T+1d
-0.36%
call -0.36% · α +0.36%
$91.84
settled 13d ago
T+5d
call — · α —
due 7d ago
T+20d
call — · α —
in 15d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

Christopher Peetz, an officer and director of Mirum Pharmaceuticals, filed a Form 144 notice of intent to sell 30,000 shares of common stock, with an approximate market value of $2.88 million based on the filing date. The shares were acquired via stock option exercise on the same day, suggesting a cashless exercise-and-sell transaction. While the sale is modest relative to Peetz's remaining holdings (40,985 shares worth ~$3.77 million as of March 2026), the filing signals insider intent to monetize equity ahead of any potential catalyst.

Actionable Insight

This is a routine insider monetization via option exercise, not a distress signal. The sale is moderate in size relative to the insider's total position and the company's $6.2B market cap. Monitor for actual Form 4 filings to confirm execution. No immediate trading action warranted.

Key Facts

  • Insider Christopher Peetz (officer and director) filed Form 144 to sell 30,000 shares
  • Sale value approximately $2.88 million based on filing date
  • Shares were acquired via stock option exercise on June 1, 2026
  • Peetz retains 40,985 shares (worth ~$3.77 million as of March 2026)
  • Sale represents ~42% of total holdings (30,000 / 70,985 shares)
  • No lock-up expiration or earnings catalyst mentioned in filing

Financial Impact

Proposed sale of 30,000 shares valued at ~$2.88 million, representing ~42% of insider's disclosed holdings

insider holdingsdilution

Risk Factors

  • Insider may be reducing exposure ahead of a catalyst or earnings event not disclosed in this filing
  • Form 144 is intent to sell; actual sale may not occur or may differ in size/timing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (19 analysts)

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-005448
Document: 0001950047-26-005448-index.html0001950047-26-005448
Document: 0001950047-26-005448.txt0001950047-26-005448
10 reports for MIRM
Performance horizon
67% Hit rate 2 of 3 directional calls best @ T+5▲ +14.39%Apr 27, 2026
Filters
Rows
Reports for MIRM — sortable, filterable
Type Now
Jun 11, 2026
3d ago
Institutional Cluster
BULLISH ★ 6/10
$98.66 awaiting T+1awaiting T+1$99.35 (+0.69%)
Jun 10, 2026
5d ago
Insider Cluster
NEUTRAL ★ 3/10
$95.52 awaiting T+1awaiting T+1$99.35 (+4.00%)
Jun 2, 2026
12d ago
Insider Cluster
NEUTRAL ★ 2/10
$91.84 $92.49▲ +0.71%▲ +0.31%$99.35 (+8.18%)
Jun 1, 2026
13d ago
144
NEUTRAL ★ 3/10
$92.17 $91.84▼ −0.36%▲ +0.36%$99.35 (+7.78%)
Jun 1, 2026
13d ago
144
NEUTRAL ★ 2/10
$92.17 $91.84▼ −0.36%▲ +0.33%$99.35 (+7.78%)
May 18, 2026
27d ago
8-K
MIXED ★ 6/10
$95.65 $96.95▲ +1.36%▲ +0.32%$99.35 (+3.86%)
May 4, 2026
5w ago
8-K
BULLISH ★ 6/10
$105.79 $105.81▲ +0.02%▼ −0.78%$99.35 (−6.09%)
Apr 27, 2026
6w ago
8-K
BULLISH ★ 8/10
$92.48 $94.00▲ +1.64%▲ +2.13%$99.35 (+7.42%)
Apr 15, 2026
8w ago
144
NEUTRAL ★ 2/10
$95.86 $97.95▲ +2.18%▲ +0.97%$99.35 (+3.64%)
Feb 25, 2026
15w ago
8-K
BULLISH ★ 8/10
$108.62 $92.19▼ −15.13%▼ −14.58%$99.35 (−8.54%)
Showing 10 of 10

US Market Status

Market Closed — Opens in 4h 31m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access